Motor neuron diseases News and Research

RSS

U-M Health neurosurgeons complete first human implant of wireless brain computer interface

Neurosurgeons at University of Michigan Health completed the first-in-human implant of a Paradromics Inc., wireless brain-computer interface, or BCI, as part of a national clinical trial for patients with difficulty speaking.

17 Jun 2026

Game-changing discovery reveals how viruses may trigger ALS development

A large, multidisciplinary team led by researchers from Texas A&M University has made a potentially game-changing discovery about the development of devastating motor neuron diseases like amyotrophic lateral sclerosis (ALS).

27 Jan 2026

Prolonged exposure to air pollution linked to elevated risk for ALS

Prolonged exposure to air pollution can be linked to an elevated risk for serious neurodegenerative diseases like ALS and seems to speed up the pathological process, report researchers from Karolinska Institutet in Sweden.

20 Jan 2026

Global analysis shows rising burden of ALS and motor neuron diseases

Amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs) are major global causes of death. However, their global incidence, mortality, and disability-adjusted life years remain largely unknown, despite their importance for disease prevention and resource allocation.

27 Nov 2025

Enhancing ALS diagnosis with dual blood biomarkers

Despite modern imaging and genetic testing, diagnosing amyotrophic lateral sclerosis (ALS) remains challenging, particularly when distinguishing it from clinically similar neurodegenerative disorders.

29 Oct 2025

New UAB-developed gene therapy for ALS receives orphan drug designation

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral Sclerosis (ALS) developed at the Universitat Autònoma de Barcelona and licensed to the U.S. company Klotho Neurosciences, Inc.

15 Jul 2025

ALL ALS Consortium creates a central information hub to accelerate ALS research

The Access for All in ALS (ALL ALS) Consortium announced the launch of its official website, creating a central hub for information about its initiatives and clinical research studies. ALL-ALS.org is designed to inform and engage researchers, clinicians, and current and prospective study participants.

31 Mar 2025

First insights into familial ALS in Egypt reveal genetic variations and disease progression

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and eventually death.

18 Feb 2025

Groundbreaking ALS platform trial accelerates research and drug testing

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, has been working with national and international stakeholders to accelerate ALS research by launching the first platform trial in ALS to simultaneously test multiple drugs using shared trial infrastructure and placebo data.

17 Feb 2025

New insights into stiff-person syndrome, advancing diagnosis and treatment

Research explores the complexities of diagnosing and treating stiff-person syndrome, emphasizing the uncertain role of GAD antibodies and the promise of novel therapies.

5 Sep 2024

Study proposes novel approach to slow neuromuscular degeneration in ALS patients

A study led by the Center for Biomaterials and Tissue Engineering of the Universitat Politècnica de València, member of Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine, in collaboration with the Instituto de Investigación Sanitaria La Fe and the University of Zaragoza proposes a novel approach to slow neuromuscular degeneration in patients with Amyotrophic Lateral Sclerosis.

20 Feb 2024

Axon Biology & The Future of Drug Discovery: A Deep Dive with Dr Federico Dajas-Bailador

News-Medical sits down with Dr. Federico Dajas-Bailador, a leading expert in axon biology and drug discovery.

From ELRIG (UK) Ltd. 31 Oct 2023

JPND announces call for multinational research on understanding the mechanisms of non-pharmacological interventions

The EU Joint Programme - Neurodegenerative Disease Research (JPND) initiative has announced a joint transnational call for multinational research on understanding the mechanisms of non-pharmacological interventions.

10 Jan 2022

Targeting the brain should be the focus of ALS therapy, not just spinal cord

The brain is indeed a target for treating ALS (amyotrophic lateral sclerosis), Northwestern Medicine scientists have discovered.

4 Dec 2021

Scientists identify new compound that reverses ALS neuron damage

Northwestern University scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a key contributor to ALS (amyotrophic lateral sclerosis), a swift and fatal neurodegenerative disease that paralyzes its victims.

23 Feb 2021

Antiepileptic drug reduces early signs of clinical dysfunction in people with ALS

The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital.

10 Dec 2020

Study reveals new biomarker for amyotrophic lateral sclerosis

ALS is a fatal neurodegenerative disease causing a rapid loss of motor function, which usually results in a serious condition with early death within a few years.

9 Dec 2020

Experimental ALS drug shows potential to prolong patient survival

An experimental medication that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has now demonstrated the potential to also prolong patient survival.

16 Oct 2020

Study implicates new gene as driver of motor neuron diseases

Failures in a quality control system that protects protein-building fidelity in cells can lead to motor neuron degeneration and related diseases, according to a new study from an international team co-directed by Scripps Research molecular biologist Claudio Joazeiro, PhD.

16 Sep 2020

Experimental drug for ALS shows promising results in clinical trial

An experimental medication slows the progression of the neurodegenerative disease called Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to recently released results from a clinical trial run by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Amylyx Pharmaceuticals, Inc., the company that manufactures the medication.

2 Sep 2020